Daniel Kripke, M.D.
Daniel F. Kripke, M.D. is a licensed physician certified by the American Board of Psychiatry and Neurology and an Emeritus Professor of Psychiatry at the University of California, San Diego. He also has done research with the Scripps Clinic Viterbi Family Sleep Center. Dr. Kripke was elected a Fellow of the American Psychiatric Association, co-authored hundreds of medical articles and has given invited lectures in 18 countries. In 1973, Dr. Kripke established one of the first sleep clinics in the United States. He treated patients with sleep disorders until retirement from his clinical practice at age 70. Dr. Kripke continues to be active as a researcher and as an advocate for raising awareness of the dangers associated with sleeping pills, particularly hypnotic drugs.
Dr. Kripke’s research has shown that hypnotic drugs, especially certain benzodiazepines and Z drugs with similar actions on the brain, have the potential to cause infection, depression, and are associated with increased risk of death and cancer. Dr. Kripke’s desire in joining Benzodiazepine Information Coalition is to inform the public about the grave risks of these drugs.
Learn more about Dr. Kripke’s research at The Dark Side of Sleeping Pills.
- Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit
- What do hypnotics cost hospitals and healthcare?
- Do hypnotic drugs cause cancer, like cigarettes?
- Possibility that certain hypnotics might cause cancer in skin.
- I petitioned the FDA to restrict hypnotics: here is why.
- Mortality Risk of Hypnotics: Strengths and Limits of Evidence.
- “Rebound” is not an appropriate criterion for withdrawal insomnia.
- Hypnotics cause insomnia: evidence from clinical trials.
- Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.
What will participation involve? This project involves a series of online surveys to be completed over a six-month period. They will involve questions about your demographics, benzodiazepine use and experiences with them, as well as a few questions relating to your...read more
In observation of the fourth annual World Benzodiazepine Awareness Day (W-BAD), occurring on July 11, 2019, BIC is sponsoring a fundraising event. How to Participate? Launch a Facebook fundraiser on your page between now and July 12 (July 12 should be the end date)...read more
Sudden cessation of benzodiazepines is highly dangerous, with the possibility of seizures, severe and/or protracted withdrawal syndrome, and even death. A sensible taper plan can avoid the risk of seizures and mitigate, although not eliminate, withdrawal symptoms.read more
A taper is a gradual reduction in benzodiazepine dosage. Depending on your individual situation, a taper may last weeks, months, or even years.read more
There are numerous ways of tapering, including cut-and-hold, microtaper (via scale or liquid titration), compounding and taper strips. You may choose to taper from your original drug or “crossover” to a longer acting benzodiazepine. For more information go here.read more
“Half-life” is the amount of time for the concentration of drug in the blood to fall by 50 percent. This time-period will vary between individuals. Commonly used “short” half-life benzodiazepines include Ativan and Xanax, while “long” half-life benzodiazepines include...read more
There is not yet adequate awareness in the U.S for the FDA to require this of manufacturers.read more
Kindling refers to the neurological condition resulting from repeated withdrawal episodes from sedative–hypnotic drugs such as alcohol and benzodiazepines. Each withdrawal leads to more severe withdrawal symptoms than the previous withdrawal syndrome. Individuals who...read more
Many patients are told they are doing a slow taper, when they are actually doing a fast taper. The rule of thumb is not more than 5-10% of the current dose every 2-4 weeks. Most tapers take 10 months or much longer.read more
All benzodiazepines have an estimated dose that is equivalent to doses of other benzodiazepines. Unlike opiates, equivalence conversions between different benzodiazepines are not defined or required by the FDA. Evidence-based information on benzodiazepine equivalents...read more